All Members

Biogen Latvia

Industry: Healthcare/Pharmaceuticals
Website: http://www.biogen.com
Level: Corporate Contributing

Biogen Latvia is a US-based company and one of the world's largest biotechnology companies for the development and commercialization of therapies specializing in neurological disease research. Biogen was founded in 1978 and is one of the largest biotech companies, employing more than 7400 employees worldwide. The company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Biogen's turnover in 2019 was 14.4 billion US dollars.

< Back to Members

Feedback

In Nasdaq we strive to build sustainable principles into our solutions because it is the key to long-term global prosperity. AmCham is an organization where well-governed and transparent companies of different sizes and origins meet. This is why I am delighted to contribute to improving the business culture and corporate governance through AmCham.

Liene Dubava, Chair of the Management Board of Nasdaq Riga Stock Exchange

Roche Latvija is pleased to be part of the AmCham community.

Rauls Vēliņš, General Manager, Roche Latvija